Comparative Pharmacology
Head-to-head clinical analysis: SOTRET versus ZENATANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SOTRET versus ZENATANE.
SOTRET vs ZENATANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription to reduce sebum production, normalize follicular keratinization, and inhibit Propionibacterium acnes growth.
Isotretinoin (13-cis-retinoic acid) reduces sebaceous gland size and inhibits sebum production by binding to nuclear retinoic acid receptors (RARs and RXRs), altering gene expression involved in cell differentiation and apoptosis.
Oral isotretinoin 0.5-1 mg/kg/day divided twice daily for 15-20 weeks.
0.5 mg/kg orally once daily, titrated up to 1 mg/kg/day based on response; maximum 2 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life: 18-20 hours in adults; steady-state achieved after 5-7 days of dosing.
Clinical Note
moderateIsotretinoin + Estrone sulfate
"The therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Estramustine
"The therapeutic efficacy of Estramustine can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Dienogest
"The therapeutic efficacy of Dienogest can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Medroxyprogesterone acetate
Terminal elimination half-life is 16-22 hours (mean 19 hours) in adults. Steady-state achieved in 3-5 days. Half-life may be prolonged up to 40 hours in severe renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism with renal excretion of metabolites (approximately 60-80% in urine) and fecal elimination (15-30%).
Primarily renal excretion as unchanged drug (60-70%) and glucuronide conjugates (10-20%). Fecal elimination accounts for 10-15% via biliary secretion.
Category C
Category C
Retinoid
Retinoid
"The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Isotretinoin."